Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

被引：5

作者：

Ramalingam, Suresh S. ^{[1
]}

Saka, Hideo ^{[2
]}

Ahn, Myung-Ju ^{[3
]}

Yu, Helena ^{[4
]}

Horn, Leora ^{[5
]}

Hida, Toyoaki ^{[6
]}

Cantarini, Mireille ^{[7
]}

Verheijen, Remy ^{[7
]}

Wessen, Jonathan ^{[7
]}

Oxnard, Geoffrey ^{[8
]}

Ohe, Yuichiro ^{[9
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan

[3] Samsung Med Ctr, Seoul, South Korea

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Aichi Canc Ctr, Nagoya, Aichi, Japan

[7] Astrazeneca, Global Med Dev, Cambridge, England

[8] Dana Farber Canc Inst, Boston, MA 02115 USA

[9] Natl Canc Ctr, Tokyo, Japan

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT034

引用

页数：2

共 50 条

[31] SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
Yu, Y.
Yang, N.
Zhang, Y.
Zhang, H.
Li, M.
Yu, Q.
Zhou, J.
Hu, X.
Fang, J.
Zhao, H.
Feng, J.
Li, L.
Shu, Y.
Wang, X.
Sun, M.
Zhang, J.
Li, M.
Ren, Y.
Lu, S.
ANNALS OF ONCOLOGY, 2022, 33 : S1553 - S1553
[32] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
Oxnard, Geoffrey R.
Cantarini, Mireille
Frewer, Paul
Hawkins, George
Peters, Jane
Howarth, Paul
Ahmed, Ghada F.
Sahota, Tarjinder
Hartmaier, Ryan
Li-Sucholeiki, Xiaocheng
Ahn, Myung-Ju
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[33] The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study
Hartmaier, Ryan
Han, Ji-Youn
Ahn, Myung-Ju
Cho, Byoung Chul
Cantarini, Mireille
Frewer, Paul
Frigault, Melanie M.
Oxnard, Geoffrey
CANCER RESEARCH, 2020, 80 (16)
[34] Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
Riess, Jonathan W.
Krailo, Mark D.
Padda, Sukhmani Kaur
Groshen, Susan G.
Wakelee, Heather A.
Reckamp, Karen L.
Koczywas, Marianna
Piotrowska, Zofia
Steuer, Conor Ernst
Kim, Chul
Paweletz, Cloud P.
Sholl, Lynette M.
Heavey, Grace
Kolesar, Jill
Moscow, Jeffrey
Janne, Pasi A.
Lara, Primo
Newman, Edward M.
Gandara, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[35] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Passaro, A.
Wang, J.
Wang, Y.
Lee, S. -H.
Melosky, B.
Shih, J. -Y.
Wang, J.
Azuma, K.
Juan-Vidal, O.
Cobo, M.
Felip, E.
Girard, N.
Cortot, A. B.
Califano, R.
Cappuzzo, F.
Owen, S.
Popat, S.
Tan, J. -l.
Salinas, J.
Tomasini, P.
Gentzler, R. D.
William, W. N.
Reckamp, K. L.
Takahashi, T.
Ganguly, S.
Kowalski, D. M.
Bearz, A.
MacKean, M.
Barala, P.
Bourla, A. B.
Girvin, A.
Greger, J.
Millington, D.
Withelder, M.
Xie, J.
Sun, T.
Shah, S.
Diorio, B.
Knoblauch, R. E.
Bauml, J. M.
Campelo, R. G.
Cho, B. C.
ANNALS OF ONCOLOGY, 2024, 35 (01) : 77 - 90
[36] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Moik, F.
Riedl, J. M.
Ay, C.
ANNALS OF ONCOLOGY, 2024, 35 (03) : 327 - 327
[37] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
Planchard, D.
Boyer, M.
Lee, J-S.
Dechaphunkul, A.
Cheema, P.
Takahashi, T.
Todd, A.
McKeown, A.
Rukazenkov, Y.
Ohe, Y.
ANNALS OF ONCOLOGY, 2018, 29 : 169 - 169
[38] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
Planchard, D.
Boyer, M.
Lee, J-S.
Dechaphunkul, A.
Cheema, P.
Takahashi, T.
Todd, A.
McKeown, A.
Rukazenkov, Y.
Ohe, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S72 - S73
[39] Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
Elghawy, Omar
Barsouk, Adam
Reed-Guy, Lauren
Stalker, Margaret
Sussman, Jonathan
Robinson, Kyle
Kosteva, John
Singh, Aditi
Cohen, Roger B.
Langer, Corey
Ciunci, Christine
D'Avella, Christopher
Sun, Lova
Marmarelis, Melina E.
Aggarwal, Charu
CLINICAL LUNG CANCER, 2025, 26 (02)
[40] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
Li, Meifang
Lin, Cheng
Lin, Jinghui
Chen, Shijie
Weng, Lihong
He, Zhiyong
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101

← 1 2 3 4 5 →